XML 16 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities:    
Net income (loss) $ 2,376,915 $ (3,737,795)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:    
Depreciation and amortization 1,244,104 1,351,018
Stock compensation 229,502 541,921
Gain on sale of real estate assets, net (4,453,968) (2,018,095)
Impairment of goodwill and real estate assets 26,943 95,548
Amortization of financing costs 68,923 90,080
Amortization of below-market leases (1,022) (1,244)
Amortization of deferred leasing costs 0 1,936
Straight-line rent adjustment (84,822) (91,806)
Changes in operating assets and liabilities:    
Other assets 567,686 347,695
Accounts payable and accrued liabilities 632,647 (607,021)
Accrued real estate taxes (902,471) (700,798)
Net cash used in operating activities (118,905) (866,768)
Cash flows from investing activities:    
Real estate acquisitions (4,270,192) (2,238,497)
Additions to buildings and tenant improvements (568,555) (1,279,807)
Proceeds from sale of marketable securities 0 44,602
Proceeds from sales of real estate, net 18,391,811 12,642,264
Net cash provided by investing activities 13,553,064 9,168,562
Cash flows from financing activities:    
Proceeds from mortgage notes payable, net of issuance costs 2,979,052 2,367,949
Payment of debt issuance costs (61,914) (18,131)
Repayment of mortgage notes payable (11,379,734) (7,860,474)
Payment of deferred offering costs (60,000) (16,745)
Distributions to noncontrolling interests (216,659) (1,803,357)
Contributions from noncontrolling interests 0 200,000
Dividends paid to Series D Preferred Stockholders (579,575) (522,032)
Net cash used in financing activities (9,513,802) (7,652,790)
Net (decrease) increase in cash equivalents and restricted cash 3,920,357 649,004
Cash, cash equivalents and restricted cash - beginning of period 8,036,496 6,510,428
Cash, cash equivalents and restricted cash - end of period 11,956,853 7,159,432
Supplemental disclosure of cash flow information:    
Income taxes paid 46,511 0
Non-cash financing activities:    
Paid building and tenant improvements from prior year (207,847) (295,567)
Unpaid building and tenant improvements 0 48,207
Dividends payable 192,232  
Mortgage Notes [Member]    
Supplemental disclosure of cash flow information:    
Interest paid 1,335,280 1,432,639
Series D Preferred Stock [Member]    
Cash flows from financing activities:    
Repurchase of Series D Preferred Stock, at cost (194,972) 0
Non-cash financing activities:    
Dividends payable 192,232 174,011
Conduit Pharmaceuticals Inc [Member]    
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:    
Net loss in Conduit Pharmaceuticals fair value marketable securities 176,658 3,861,233
All Other Than Conduit [Member]    
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:    
Net loss in Conduit Pharmaceuticals fair value marketable securities $ 0 $ 560